Medical economics

Pfizer to buy Array BioPharma in deal worth $11.4 billion

Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

page 1 from 23